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Abstract
Objective: This cross-sectional study examined, for the first time, a large cohort of patients with trigeminal neuralgia, to
ascertain the occurrence of familial cases, providing a systematic description of clinical features of familial disease.
Since there is evidence linking hyperexcitability of trigeminal ganglion neurons to trigeminal neuralgia, we also carried
out an exploratory genetic analysis of the neuronal electrogenisome in these patients.
Methods: We recorded familial occurrence by systematically interviewing all patients with a definite diagnosis of
classical or idiopathic trigeminal neuralgia. We found 12 occurrences of trigeminal neuralgia with positive family history
out of 88 enrolled patients. Whole-exome sequencing was carried out in 11 patients. We concentrated on the genetic
variants within a 173-gene panel, comprising channel genes encoding sodium, potassium, calcium, chloride, transient
receptor potential channels, and gap junction channels. Gene expression profiles were based on published RNA sequen-
cing datasets of rodent/human trigeminal ganglia tissues, with a focus on genes related to neuronal excitability.
Results: In patients with familial trigeminal neuralgia, pain was more often located in the right, second division.
All patients reported triggers. Four patients experienced concomitant continuous pain. Whole-exome sequencing ana-
lysis within the trigeminal ganglion electrogenisome identified 41 rare variants in ion channels, consisting of variants in
sodium channels (6), potassium channels (10), chloride channels (5), calcium channels (7), transient receptor potential
channels (12), and gap junction channels (1). In one patient, a previously profiled gain-of-function mutation in SCN10A
(Nav1.8 p.Ala1304Thr), previously reported in painful neuropathy, was found; this variant was not present in unaffected
siblings.
Conclusions: Our results suggest that familial occurrence of trigeminal neuralgia is more common than previously
considered. Although our results demonstrate variants in genes encoding voltage-gated ion channels and transient
receptor potential channels within these patients, further study will be needed to determine their roles in the patho-
genesis of trigeminal neuralgia.
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Background
Trigeminal neuralgia (TN) is a unique neuropathic
facial pain condition, characterized by unilateral parox-
ysmal pain, evoked by trigger factors (1). A subgroup
of patients suffers from TN with concomitant continu-
ous pain, described as dull, burning or aching (atypical
TN). Recent diagnostic criteria distinguish TN as
‘‘classical’’; that is, related to neurovascular compres-
sion producing morphological changes on the trigem-
inal root, ‘‘secondary’’ to a major neurological disease,
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or ‘‘idiopathic’’ with unknown aetiology (1,2). Genetic
factors may play a role in the pathophysiology of TN:
this hypothesis is suggested by the younger age of TN
patients without neurovascular conflict (3).
Although TN usually occurs in a sporadic fashion,
rare familial occurrences have been described (4–9).
The occurrence of familial TN strongly supports a gen-
etic, presumably multifactorial and polygenic, origin of
TN. In this cross-sectional study, we set out to deter-
mine, for the first time, the occurrence of familial cases
in a large cohort of patients with classical and idio-
pathic TN, and to provide a systematic description
of clinical features in these familial cases. Since hyper-
excitability of trigeminal ganglion neurons may con-
tribute to the pathophysiology of TN (10–13), we
carried out whole exome sequencing, filtered to focus
on the electrogenisome of trigeminal ganglion neurons,
in patients with familial occurrence. Given the postu-
lated multifactorial and polygenic origin of TN, this
exploratory genetic analysis provides a stepping-stone
toward future studies on larger numbers of genes and
with larger numbers of patients, unrelated controls and
healthy family members.
Methods
Standard protocol approvals, registrations, and
patient consents
The study was approved by the Ethic Committee
of Sapienza University (reference 649/17). Written
informed consent was obtained from each participant.
Clinical assessment
In this cross-sectional study, we prospectively screened
consecutive patients attending the Center for
Neuropathic Pain at Sapienza University, from
January 2017 to January 2019. The inclusion criterion
was a definite diagnosis of TN according to ICHD-3
beta criteria and the 2018 update, including 13.1.1.1
Classical TN and 13.1.1.3 Idiopathic TN. Exclusion
criteria were a diagnosis of secondary TN, related to
a major neurological disease, a diagnosis of orofacial
pain other than TN, and cognitive disturbances or
communication barriers. The diagnosis of TN was
confirmed by two clinicians.
Each patient underwent a clinical examination with
sensory profiling using bedside tools (14,15), trigeminal
reflex testing (16,17), and a dedicated 3T MRI, with
specifications optimized for identification of the TN
etiology (2,18).
Familial occurrence was systematically investigated
using a dedicated questionnaire, including demographic
data and clinical characteristics, encompassing details
of trigger factors and possible concomitant continuous
pain (Supplemental Data). When a familial occurrence
was reported, more information about the diagnosis of
TN was acquired (i.e. the center where the diagnosis
was carried out, the clinical notes, the prescribed
pharmacological or surgical treatment) and verified by
at least two clinicians. We included patients in the
familial group only when a certified diagnosis provided
by a dedicated center for the management of facial pain
was available. As a further criterion, we considered the
response to specific drugs; that is, carbamazepine,
oxcarbazepine or phenytoin. Familial occurrence was
corroborated by the pedigree analysis showing a familial
occurrence in at least one first- or second-degree relative.
In any cases where the level of the available information
was deemed as insufficient to support the evidence of a
TN diagnosis, the record was not included for the pur-
poses of our analysis. Trigger zone overlap profiling in
patients with familial and sporadic occurrence of TN
was provided using dedicated software (19).
Patients 1 to 10 and 12 underwent blood sampling
for the genetic analysis.
Whole-exome sequencing (WES)
Genomic DNA was extracted from whole blood of 11
cases and two unaffected siblings (a brother and a
sister) of TN4 (TN1-10 and TN12) with informed con-
sent using NucleoSpin Tissue kit (#740952, Machery-
Nagel, Duren, Germany) according to the manufac-
turer’s instructions. Exome library preparation and
sequencing were performed by the Yale Center for
Genome Analysis. Briefly, 1 mg of genomic DNA was
sheared into fragments with the Covaris E220 system
(Covaris, Woburn, MA, United States), followed by
end-repair, A-tailing, ligation of multiplexing adaptors,
and pre-capture ligation-mediated PCR amplification.
The quantification and insert size distribution of prod-
uct were determined using Caliper LabChip GX system
(PerkinElmer Inc., Santa Clara, CA, USA). Exome
library was captured using IDT xGen Exome Research
Panel V1.0 (Integrated DNA Technologies, Coralville,
IA, USA), and quantified by qRT-PCR using a commer-
cially available kit (KAPA Biosystems, Wilmington MA,
USA). Libraries were then loaded onto S4 flowcell and
sequenced on the Illumina NovaSeq6000 platform using
101bp paired-end sequencing reads according to
Illumina protocols (Illumina Inc., San Diego, CA, USA).
WES data analysis
The obtained reads were aligned to the human genome
reference (UCSC Genome Browser, hg19) using the
BWA-MEM aligner. Picard MarkDuplicates was used
to mark PCR duplicates, and then the GATK indel
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realignment and base quality score recalibration tools
were applied to generate the final BAM files. GATK
HaplotypeCaller was utilized to generate GVCF files
for each sample, then they were joint-called to create
the initial VCF file of variant calls. The VCF files were
then processed for filtering and annotation using
Biomedical Genomics Workbench (Qiagen, Hilden,
Germany) and in-house R scripts. A coverage depth
cutoff of 10-fold and alteration frequency cutoff of
30% were applied. All variants detected in our patients
were checked against the databases of gnomAD (The
Genome Aggregation Database, https://gnomad.
broadinstitute.org/), ExAC (The Exome Aggregation
Consortium, http://exac.broadinstitute.org), 1000 gen-
omes (https://www.ncbi.nlm.nih.gov/variation/tools/
1000genomes/), dbSNP (https://www.ncbi.nlm.nih.
gov/snp/), ESP (http://evs.gs.washington.edu/EVS/),
UK10K (https://www.uk10k.org/data_access.html),
and Yale whole-exome database. Five in-silico tools
were utilized to predict the pathogenicity of these vari-
ants: SIFT, PolyPhen-2, Mutation Assessor (MA),
FATHMM (Functional Analysis through Hidden
Markov Models), and CONDEL (Consensus deleter-
iousness score) (20–24). We also annotated all genes
using the Human Pain Genes Database (https://human-
paingenetics.org/hpgdb/), which contains >330 pain-
associated genes. Gene expression profiles were
obtained from published RNA sequencing datasets of
rodent/human trigeminal ganglia tissues. These data-
sets consist of mouse (GSE100175) (25), rat
(GSE96765) (26), and human (27). Gene expression
level was estimated using the mean value of normalized
FPKM (Fragments Per Kilobase of gene per Million
mapped reads) separately in each dataset. Because the
sequencing depth of mouse/rat/human samples varied
dramatically, the absolute values should not be com-
pared between different species.
Variant validation
Genomic DNA was amplified using High Fidelity,
AccuPrime Taq DNA Polymerase according to manu-
facturer’s protocol (ThermoFisher Cat#12346-086).
Thermal cycling was initiated at 94C for 2minutes fol-
lowed by 35 cycles of 15 s at 94C, annealing for 30 s at
55C, and an extension for 60 s at 68C. PCR ampli-
cons were sequenced at the Keck DNA Sequencing
facility at Yale University. The sequencing data was
analyzed using Biomedical Genomics Workbench
(Qiagen, Hilden, Germany).
Statistical analysis
The Mann-Whitney test was used to compare the onset
age of TN between groups; that is, familial and
sporadic TN, given that this demographic data did
not have a normal distribution. For comparisons of
categorical data, such as the clinical characteristics,
we used Fisher’s exact test or Chi-squared tests.
Findings
We have screened 112 patients with a definite diagnosis
of TN. We excluded 22 patients: 17 with TN secondary
to multiple sclerosis, three patients with a benign tumor
of the posterior fossa, one patient with TN secondary
to a superior cerebellar artery aneurysm, and one
patient with megadolicobasilar artery. Thus, we
included in the analysis 88 patients with classical or
idiopathic TN (62 females, 26 men; age 65 12.4).
Fourteen cases of possible familial occurrence of TN
were found, but two patients were excluded from the
analysis given that a certified diagnosis provided by a
dedicated center for the management of facial pain
could not be obtained. In the end, 12 occurrences of
possibly hereditary TN (seven female, five males, 10
families; age 64 12) were included in the familial
group. We defined these cases as possibly hereditary
on the basis of the diagnosis of TN in at least one
first- or second-degree relative, according to the pedigree
(Supplemental Data, Figure e-1). Eleven index patients
and two unaffected relatives underwent genetic analysis.
Case series of familial TN
Clinical characteristics of case series are summarized
in Table 1.
Case 1 was a 61-year-old woman whose two brothers
suffered from TN. Paroxysmal pain was evoked by
talking, chewing and the light touch of the nasal
wing. MRI showed a neurovascular conflict producing
dislocation and atrophy of the trigeminal root.
Case 2 was a 45-year-old woman whose grand-
mother suffered from TN. Paroxysmal pain was
evoked by eating, drinking, tooth brushing and light
touch of the cheek and lower eyelid. MRI showed dis-
location and atrophy of the trigeminal root at the site
of the neurovascular conflict.
Case 3 (brother of case 1) was a 65-year-old man
suffering from atypical TN. Paroxysms were evoked
by talking, chewing, tooth brushing, washing the face
and tactile stimulation of trigger zones including con-
junctival fornix, nasal wing, upper lip, chin, alveolar
gingiva and scalp. MRI showed a contact between
trigeminal root and superior cerebellar artery, without
morphological changes on the trigeminal root. The
patient was refractory to pharmacological treatment
and underwent microvascular decompression in the
posterior fossa with reduction in number of attacks
per day.
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Case 4 was a 73-year-old man whose father suffered
from TN. TN started with purely paroxysmal pain and,
after an interval of nine years without any symptoms,
the patient developed an atypical form of TN.
Paroxysms were evoked by chewing and light touch
of supraorbital region, external side of the eye and
upper lip. MRI identified a dislocation of the trigeminal
root with two conflicting vessels: the superior cerebellar
artery located supero-medially to the root and a vein
located superiorly.
Cases 5 and 6 were father and daughter respectively.
The father suffered from purely paroxysmal pain evoked
by talking, chewing and light touch of lower eyelid, nasal
wing and upper lip. Standard MRI excluded secondary
TN related to major neurological diseases but a dedi-
cated study of the site of neurovascular conflict was
not available. The age of onset of TN in the daughter
was 22, an extremely uncommon feature in classical TN.
She suffered from atypical TN. Trigger maneuvers
included chewing and tooth brushing; trigger zones
were located in the upper and lower lip. MRI did not
identify a neurovascular conflict. The patient was refrac-
tory to first line treatment and underwent stereotactic
radiosurgery with complete pain relief.
Case 7 was a 61-year-old man, whose mother was
affected. Paroxysmal pain was evoked by talking, chew-
ing, washing his face and gently touching chin, cheek
and upper lip. After 15 years, concomitant continuous
pain developed in the third trigeminal division. MRI
showed a neurovascular conflict producing dislocation
and atrophy of the trigeminal root.
Case 8 was a 76-year-old woman whose aunt was
affected by TN. She suffered from atypical TN.
Paroxysms were evoked by chewing, washing her face,
pronouncing labial letters and gently touching the
scalp, nasal wing, upper and lower lip. MRI showed a
bilateral neurovascular conflict with morphological
changes on the affected side.
Case 9 was a 78-year-old woman whose father and
uncle (father’s brother) were affected by TN. As trigger
maneuvers, patient reported talking, swallowing and
washing her face. Trigger zones were reported on the
upper and lower lip and chin. MRI did not identify a
neurovascular conflict. The patient could not assume
full dosage of first line drugs due to intolerable side
effects and a surgical procedure was recommended;
however, follow up data were not available.
Case 10 was a 77-year-old woman whose father was
affected by TN. Medical history was notable for idio-
pathic hemifacial spasm on the right side. Pain was
triggered by talking and eating but no extraoral triggers
were detected. Dedicated MRI did not identify a neu-
rovascular conflict. Pharmacological treatment with
oxcarbazepine produced side effects on the central ner-
vous system that required a dosage reduction to an
unsatisfactory level.
Case 11 was a 53-year-old woman whose sister was
affected by TN. Pain was triggered by talking, eating
and gently touching the face. Dedicated MRI identified
a neurovascular conflict producing dislocation and
atrophy on the trigeminal root. The patient was refrac-
tory to pharmacological standard treatment.
Table 1. Case series of familial TN.
Case
Classical/
Idiopathic
Affected
relatives Age Gender
Age at
onset
Affected
division Side
Concomitant
continuous
pain (Y/N),
division, side
Remission
periods
(Y/N) Drug/response
TN1 Classical Two brothers 61 Female 60 V2 Left N N OXC 600mg/pain relief
TN2 Classical Grandmother 45 Female 39 V2-V3 Right N N OXC 1200mg/pain relief
TN3 Idiopathic Sister 65 Male 43 V1-V2-V3 Right Y, V2, Right Y Refractory
TN4 Classical Father 73 Male 63 V1-V2 Right Y, V1-V2, Right Y CBZ 1000mg/pain relief
TN5 Unknown Daughter 72 Male 64 V1-V2 Right N N Refractory
TN6 Idiopathic Father 43 Female 22 V1-V2-V3 Right Y, V1-V2-V3,
Right
N Refractory
TN7 Classical Mother 61 Male 46 V2-V3 Left Y, V3, Left Y OXC 1800mg/pain relief
TN8 Classical Aunt 76 Female 50 V2-V3 Left Y, V2-V3, Left Y OXC 900mg/pain relief
TN9 Idiopathic Father,
father’s
brother
78 Female 64 V2-V3 Right N Y Drop out for AEs
TN10 Idiopathic Father 77 Female 71 V1-V2-V3 Right N Y Drop out for AEs
TN11 Classical Sister 53 Female 43 V3 Right N Y Refractory
TN12 Classical Father 64 Male 59 V1-V2 Left N N OXC 1200mg/pain relief
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Case 12 was a 64-year-old man whose father was
affected by TN. Pain was triggered by eating and
tooth brushing; trigger zones included cheek and supra-
orbital region. Dedicated MRI identified a neurovascu-
lar conflict with a venous vessel, producing dislocation
and atrophy of the trigeminal root.
Clinical characteristics, etiology and drug response
in patients with familial and sporadic cases
Although the age at onset in patients with familial
occurrences (median 55; IQR: 43764) was earlier in
comparison with that observed in sporadic cases
(median 60; IQR: 49764), this difference did not
reach statistical significance. In one patient with famil-
ial TN, paroxysmal pain started at a very young age,
22 years old. Apart from the onset at young age in two
patients with familial TN (39 and 22 years old), there
was a substantial overlap between the two groups in the
onset age distribution.
A comparison of demographic and clinical charac-
teristics between sporadic and familial occurrences of
TN is provided in Table 2.
In patients with familial TN, as well as in patients
with sporadic TN, the second trigeminal division was
the most affected (11/12 and 56/76 respectively), fol-
lowed by the third (8/12 and 44/76) and the first (6/12
and 20/76). In both groups, the right side was more
frequently involved than the left side (8/12 and 56/76).
All patients with familial TN reported trigger fac-
tors, similarly to sporadic TN, where trigger factors
were reported in 74 cases out of 76. Overlap profiling
of trigger zones in patients with and without a family
history of TN is provided in Figure 1.
A comparable percentage of patients in both groups
(5/12 and 31/76) reported concomitant continuous pain
between the paroxysmal attacks.
The percentage of remission periods in patients with
familial and sporadic occurrences was 7/12 (58%) and
47/76 (57%), respectively.
In both classical and idiopathic TN, the same first-
choice pharmacological treatment (CBZ or OXC) was
administered (17).
Four out of 12 patients with familial occurrence
and 9/76 patients with sporadic cases were refractory
to standard pharmacological treatment. In 2/12
patients with familial TN and 15/76 patients with
sporadic cases, side-effects produced interruption of
treatment or required a dosage reduction to an unsat-
isfactory level.
In 4/12 and 21/76 cases with familial and sporadic
TN respectively, dedicated MRI did not identify a neu-
rovascular conflict producing morphological changes
on the trigeminal root: these cases were classified as
idiopathic.
Genetic analysis
WES data analysis and variant validation. Due to the pur-
ported role of hyperexcitability along the trigeminal
pathway in TN (10–13), we focused our analysis on
173 ion channel genes that are known to regulate neur-
onal excitability in peripheral sensory neurons such
as trigeminal ganglion neurons (Supplemental Data,
Table e-1). We identified 41 rare variants (minor allele
frequency< 1%) in 36 genes from 11 familial TN cases
(Table 3). The data did not show a common variant,
or variants, in the same gene in more than three unre-
lated probands. Future studies, testing these variants
in heathy family members and unrelated controls,
are needed. However, we identified potentially patho-
genic variants, and applied additional filters to narrow
down the number of variants for future functional
assessment.
It is notable that TN1 and TN3 are sister/brother,
and they share a 9-bp duplication (c.642_650dup) in the
potassium channel gene KCNC3 and a synonymous
splice site variant (c.1467G>A) in KCND2. This
splice site variant is located at the last nucleotide of a
coding exon, and this alteration is predicted to reduce
Table 2. Demographics and clinical characteristics in familial and sporadic groups.
Patients
Gender
(F/M)
Affected
side (L/R)
Affected division (% of patients)
Concomitant Trigger Remission Treatment
V1 V2 V3
p (effect
size)
continuous
pain (Y/N)
factors
(Y/N)
periods
(Y/N)
response
(Y/N)
Familial cases
n¼ 12
7/5 4/8 6 (50) 11 (92) 8 (67) 0.082 5/7 12/0 7/5 4/8
Sporadic cases
n¼ 76
55/21 20/56 20 (26) 56 (74) 44 (58) <0.01
(0.49)2
31/45 74/2 43/33 9/67
p 0.331 0.731 0.171 0.281 0.751 >0.501 >0.501 >0.501 >0.051
1Fisher’s exact test. Reported p-values refer to the comparison between the sporadic and the familial groups.
2Chi-square test. Reported p-values refer to the comparison, relevant to the most affected division, within the same group of patients.
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the splicing efficiency using multiple online tools
(28–30). Although TN1 carries a variant in TRPM8
(Arg30Gln), a gene which is known to contribute to
pain (Human Pain Genes Database), it is not shared
by her sibling.
We found rare variants in four known pain-
associated genes in TN4: SCN9A (encodes voltage-
gated sodium channel Nav1.7), SCN10A (Nav1.8),
CLIC5 (encodes Chloride Intracellular Channel 5),
and KCNJ6 (encodes ATP-sensitive inward rectifier
potassium channel 2) (Table 3). Among these genes,
SCN9A and SCN10A have been implicated in human
pain disorders (31,32). Pedigree analysis of the unaf-
fected siblings of TN4 showed that only the
p.AAla1304Thr variant in SCN10A was unique to the
affected proband; this SCN10A variant is known to
increase sensory neuron excitability and was previously
identified as pathogenic in a patient with painful per-
ipheral neuropathy (33).
TN5 and TN6 are a father/daughter pair and they
share variants in genes encoding transient receptor
potential (TRP) channels, TRPA1 (Arg393Gln) and
TRPM2 (Ser443Gly). Rare variants of TRP genes
were identified in all other TN cases except for TN7
and TN9 (Table 3). All of these variants are single-
nucleotide substitutions: TRPC6 (TN2: p.Leu288Phe),
TRPM3 (TN10: p.Ala1645Val), TRPM4 (TN8:
p.Arg337Cys), TRPM7 (TN4: p.Ala931Thr), TRPM8
(TN1: p.Arg30Gln), TRPS1 (TN8: p.Lys46Asn; TN12:
p.Ala1088Val), TRPV4 (TN12: pTyr283Asn), and
TRPV5 (TN3: p.Leu23Pro), and TRPV6 (TN12:
Ser401Arg). Only one variant was not scored as dama-
ging by any of the five in silico analyses, and three vari-
ants are classified as pathogenic by all five algorithms,
while the rest were scored as potentially pathogenic by
one or more of these tests (Table 3).
Rare variants of one gene, CLCN1, were seen in three
patients. Mutations of this gene have been linked to
autosomal dominant/recessive myotonia congenita
(34), but while expressed in trigeminal ganglia, its expres-
sion level is low. No muscle weakness or myotonia was
recorded in these patients. However, given that different
mutations in genes can cause different diseases, we
cannot exclude a priori that these rare variants in the
CLCN1 gene may contribute to TN.
Discussion
In this cross-sectional study in a large cohort of patients
with classical and idiopathic TN, we identified for the
first time a significant subset of patients with familial
occurrences; 11% of patients with a definite diagnosis
of TN reported at least one affected relative. In view
of prior evidence that hyperexcitability of trigeminal
ganglion neurons contributes to the pathophysiology
of TN (10–13), we focused our genetic assessment on
the electrogenisome. In these patients with familial TN,
our exploratory analysis showed rare variants of genes
encoding voltage-gated channels and TRP channels.
These findings support the need for further study of
possible genetic contributions to disease pathogenesis
in patients with familial TN.
Although no statistically significant difference was
found in age at onset between groups in this explora-
tory study, two patients with familial TN showed an
onset of disease at young age (before 40 years old),
an extremely rare occurrence in non-secondary TN
(16). The other clinical characteristics including affected
division, trigger factors, remission phases and the devel-
opment of concomitant continuous pain did not differ
significantly between patients with familial or sporadic
occurrences of TN (Table 2).
Sporadic TN (n = 76) Familial TN (n = 12)(a) (b)
Figure 1. Trigger zones overlap profiling in patients with sporadic (a) and familial (b) TN. The number of superimpositions ranged
from 2 (dark cyan) to 15 (dark orange), in sporadic forms, and between 2 (dark cyan) and 7 (dark orange) in familial forms.
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Table 3. All variants detected in our ion channel gene panel from 11 cases with familial TN.
Gene Case Variant Protein Pain gnomAD
Mouse
TG
Rat
TG
Human
TG SIFT PP2 MA FAM CON
SCN2A TN7 74T>C Ile25Thr  1/251012 ND 282.76 0.75 0.01 0.597 3.445 –4.57 0.68
SCN3A TN8 46C>T Leu16Phe  1/251258 0.76 134.77 0.30 0.18 0.013 –0.315 –3.89 0.47
SCN5A TN8 1019G>A Arg340Gln þ 21/279838 0.50 69.80 0.52 0.26 0.552 0.490 –3.81 0.52
SCN7A TN7 3610G>A Gly1204Arg  29/176432 21.49 10333.36 32.83 0.04 0.484 2.555 –4.16 0.61
SCN9A TN4 3269T>G Met1090Arg þ 25/276420 42.33 5164.29 12.10 0.17 0.008 0.345 –1.68 0.48
SCN10A TN4 3910G>A Ala1304Thr þ 13/282790 76.54 6030.39 8.31 0.00 0.782 3.600 –4.40 0.69
TRPA1 TN5/6 1178G>A Arg393Gln þ 6/246840 17.92 1693.49 10.85 0.47 0.001 1.61 0.98 0.45
TRPC6 TN2 864G>T Leu288Phe  / 7.51 54.64 0.26 0.00 1.000 2.775 –2.07 0.64
TRPM2 TN5/6 1327A>G Ser443Gly  34/282758 2.25 308.98 4.13 0.31 0.030 2.505 –0.16 0.59
TRPM3 TN10 4934C>T Ala1645Val  280/282824 2.56 1236.18 6.35 0.22 0.000 0.000 0.57 0.43
TRPM4 TN8 1009C>T Arg337Cys þ 36/280322 5.72 261.08 4.15 0.00 0.644 1.650 0.06 0.49
TRPM7 TN4 2791G>A Ala931Thr  / 2.88 1341.87 7.75 0.03 0.994 3.125 –5.07 0.66
TRPM8 TN1 89G>A Arg30Gln þ 9/282688 8.95 2794.57 1.61 0.32 0.689 1.240 0.21 0.49
TRPS1 TN12 3263C>T Ala1088Val  / 0.19 88.40 3.57 0.09 0.002 0.000 –5.07 0.52
TRPS1 TN8 138G>T Lys46Asn  12/249224 0.19 88.40 3.57 0.01 0.011 0.000 –5.13 0.53
TRPV4 TN12 847T>A Tyr283Asn þ 29/282600 0.30 11.43 1.01 0.00 0.843 1.940 –0.46 0.51
TRPV5 TN3 68T>C Leu23Pro  343/282814 ND 3.00 0.13 0.04 0.007 1.085 –1.57 0.53
TRPV6 TN12 1203C>G Ser401Arg  2/243612 0.06 183.24 0.08 0.51 0.003 1.320 –1.95 0.54
KCNA5 TN4 251A>C Glu84Ala  29/235714 0.32 92.94 0.31 0.70 0.001 0.000 –4.35 0.51
KCNC3 TN1/3 642_650dup Duplication  27/190394 1.52 2463.33 0.70 / / / / /
KCNC3 TN12 1706C>T Pro569Leu  16/231826 1.52 2463.33 0.70 0.61 0.008 –0.405 –4.51 0.48
KCND2 TN1/3 1467G>A Splice site þ 3/250442 0.15 ND 0.04 / / / / /
KCNH2 TN1 1489G>A Gly497Ser  / 2.33 1287.30 8.80 0.56 0.056 0.000 –5.40 0.53
KCNH7 TN2 1120G>A Val374Met  805/282206 2.40 155.04 1.58 0.06 0.993 2.430 –5.39 0.63
KCNJ6 TN4 1142T>C Leu381Pro þ 34/248948 0.48 75.15 0.09 0.22 0.908 1.100 –2.49 0.53
KCNK17 TN2 806C>T Thr269Met  2/282860 ND ND 1.66 0.08 0.006 0.000 1.85 0.39
KCNS2 TN5 850A>G Thr284Ala  420/282858 0.26 6.57 0.37 0.49 0.009 1.040 –4.90 0.57
KCNV1 TN8 1418C>T Ala473Val  16/282814 3.02 94.91 2.06 0.01 0.314 0.695 –4.49 0.55
CACNA1A TN7 7364C>A Pro2455His þ / 1.60 1544.42 5.67 0.01 0.135 0.345 –3.81 0.51
CACNA1D TN1 6032G>A Arg2011Gln  4/282448 0.25 459.04 0.94 0.27 0.002 1.610 0.54 0.47
CACNA1G TN7 2117G>A Arg706Gln  21/280006 0.04 82.35 0.10 0.07 0.920 1.355 –4.28 0.56
CACNA1I TN6 4603G>T Cys1905Ser  2/249230 0.50 147.27 0.17 0.15 0.444 0.700 –4.89 0.56
CACNA1I TN10 5714G>C Val1535Leu  116/280692 0.50 147.27 0.17 0.75 0.267 1.610 –3.99 0.56
CACNA1S TN2 5407G>A Asp1803Asn  / 0.15 1.87 0.02 0.00 0.989 2.275 0.27 0.54
CACNB1 TN10 1337C>T Pro446Leu  6/198244 4.46 706.99 10.75 0.23 0.011 1.100 –1.05 0.53
CLCN1 TN4 86A>C His29Pro  708/282226 ND 116.97 0.04 0.04 0.497 1.700 –1.98 0.54
CLCN1 TN9 501C>G Phe167Leu  308/282890 ND 116.97 0.04 0.56 0.055 0.690 –2.92 0.51
CLCN1 TN10 2666A>G Asn889Ser  2/248918 ND 116.97 0.04 0.27 0.001 0.490 –1.88 0.49
CLCN2 TN12 704G>A Arg235Gln  310/282620 ND ND 9.25 0.03 0.762 2.095 –3.49 0.57
CLIC5 TN4 799C>T His267Tyr þ / 0.03 202.85 1.26 0.17 0.242 1.440 –3.26 0.55
GJB5 TN2 65G>A Arg22His  3/251452 ND 2.73 0.06 0.00 0.999 2.390 –5.63 0.63
þ/: gene listed/not listed in the Human Pain Gene Database; Mouse/rat/human TG: mean value of normalized FPKM (Fragments Per Kilobase of gene
per Million mapped reads) of trigeminal ganglia; ND: not detected; Score: SIFT (cutoff< 0.05), PP2 (PolyPhen-2, cutoff> 0.5), MA (Mutation Accessor,
cutoff> 0.65), FA (FATHMM, cutoff<1.5), CON (CONDEL, cutoff> 0.5). /: no data.
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The percentage of patients refractory to first line treat-
ments (CBZ or OXC) in the sporadic TN group was in
line with previous data (35), reporting up to 9% of
refractory patients. Conversely, the percentage of refrac-
tory patients in the familial TN group was higher in
comparison with sporadic cases and with previous data
in a sample of 200 patients with classical TN (35). This
finding, approaching statistical significance (Table 2),
suggests that the possible mechanisms underlying familial
TN might reduce the effectiveness of voltage-gated
sodium channel blockers, such as CBZ and OXC.
Genetic analysis identified rare variants in multiple
genes which encode members of the TRP channel
family. Two of these channels, TRPA1 and TRPM8,
have been previously linked to pain (36), while the
other members of this family have not been known to
contribute to pain pathology. All of the TRP genes
identified in our analysis are known to be expressed
in peripheral sensory neurons, although some have
been reported to be expressed at relatively low levels
(25–27). TN5 and TN6 are a father/daughter pair and
they share mutations in TRPA1 and TRPM2. The
familial relationship adds weight to the possibility
that these rare variants might contribute to the patho-
physiology of TN in these patients. Thus, while the
pathogenic role of the variants in these TRP channels
is still unknown, their expression in sensory neurons
suggests a possible link to pain in TN.
In one patient (case 4), we identified a previously
profiled gain-of-function mutation in SCN10A
(Nav1.8, p.Ala1304Thr), which was previously reported
in a patient with painful peripheral neuropathy (33).
Voltage-clamp analysis revealed that this mutation
shifts channel activation 6mV in a hyperpolarizing dir-
ection. Current-clamp analysis showed that expression
of Nav1.8-A1304T in DRG neurons reduces current
threshold, increases firing frequency in response to
suprathreshold stimuli, and depolarizes resting poten-
tial, thus causing neuronal hyperexcitability of DRG
neurons (33). At a clinical level, these changes might
be expected to lower the threshold for evoked pain
and increase pain intensity. Although this patient car-
ried variants in other ion channels (Table 3), genomic
analysis of two unaffected siblings showed that only the
Ala1304Thr variant is private for the proband.
Considering the multifactorial/polygenetic origin of
TN, the presence or absence of one variant in a
family member has limited consequence on the patho-
genesis of the variant. On the contrary, the assessment
of the presence of this variant in the affected father
would have further supported the conclusion that this
mutation directly contributes to TN in this patient.
Future functional studies will be required to define
the possible pathogenicity of the variants described
in this paper, from genes of voltage gated channels
and of the TRP channel family. As with peripheral
neuropathies where mutations of ion channels appear
to contribute to the pathophysiology of a disorder with
a time-dependent (adult-onset) course (37), definitive
explication of a role of these variants in the pathophysi-
ology of TN will require demonstration of a ‘‘multi-hit
model’’ that can explain both adult onset and the focal
nature of the disorder.
Notably, although in the majority of patients with
familial TN we found a neurovascular conflict produ-
cing significant morphological changes on the trigem-
inal root (38), in 4/12 familial cases MRI investigation
did not show neurovascular compression.
A suggested pathophysiological mechanism of clas-
sical TN is the focal demyelination of primary afferents
near the entry of the trigeminal root into the pons, a
‘‘locus minoris resistentiae’’ where Schwann cells are
substituted by oligodendroglia in providing the myelin
sheath (10,39–40). There is substantial evidence that
demyelination can render axons hyperexcitable and
increase their susceptibility to ectopic excitation,
ephaptic transmission and generation of high frequency
discharges (41,42). Neurovascular contact was found in
a previous TN patient with a Nav1.6 mutation (43); this
gain-of-function mutation would be expected to exacer-
bate any hyperexcitability due to vascular compression
and/or demyelination. A gain-of-function mutation of
Nav1.8 was found in one of the patients in the present
series. While not normally present at most nodes in
normal tissue, Nav1.8 is present at nodes and hemi-
nodes in some rodent models of demyelination (44).
Nav1.6 is the predominant sodium channel at nodes
of Ranvier but, if Nav1.8 channels are expressed in
demyelinated axons in this patient with TN, they
would be expected to contribute to ectopic impulse gen-
eration and/or cross-talk.
The findings of the present study do not establish
a causal relationship, but are consistent with the
hypothesis that ion channel variants might contribute
to the pathogenesis in at least some cases of TN. This
mechanism, if confirmed, raises the question of whether
the risk:reward calculus for surgery may be different
in familial cases of TN compared with non-familial
cases, and further raises the question of whether opti-
mal treatment of TN patients carrying mutations of
ion channels might differ from that in patients who
do not carry channel mutations; genetic factors might
have an impact on response to pharmacological treat-
ment, especially in patients without severe neurovascu-
lar conflict. Further studies will be needed to answer
these questions.
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Limitations
Focusing on the electrogenisome, we identified rare
variants in 36 genes in the 11 cases of familial TN.
However, future studies, assessing a wider array of
genes and testing these variants in wider samples
of participants, including healthy family members and
unrelated controls are needed. Given the plausible
multifactorial and polygenic origin of TN, our genetic
analysis provides exploratory information, paving the
way to future studies which can examine a larger
number of genes in a larger number of patients and
controls.
The MRI investigations in the affected relatives used
heterogeneous protocols and did not allow definitive
assessment of neurovascular conflict. In particular, we
did not have the opportunity to revise MRI images
for assessment of the presence of possible trigeminal
root morphological changes at the site of conflict.
Therefore, we could not verify whether our patients
and the affected relatives suffered from the same type
of TN (classical or idiopathic). Nevertheless, given the
hypothesis of a multifactorial pathogenesis of TN,
the presence of a conflict with morphological
abnormalities might not play a crucial role in these
families. The concurrent presence of familial risk fac-
tors may increase the susceptibility of the trigeminal
root or cell body to ectopic excitation and high fre-
quency discharge generation.
Conclusions
This cross-sectional study in a large cohort of patients
with TN identified for the first time a significant subset
of patients with familial occurrence of TN (11%).
Although the difference in age at onset between
groups did not reach statistical significance, in one
case of familial TN, onset occurred at the notable age
of 22. In one patient, a gain-of-function mutation in
SCN10A (Nav1.8, p.Ala1304Thr), previously reported
in a patient with an episodic pain syndrome (33), was
detected. We also identified rare variants in other vol-
tage-gated channels and TRP channels that are part of
the neuronal electrogenisome. We conclude that famil-
ial TN is not uncommon and propose the hypothesis
that ion channel variants might contribute to pathogen-
esis in at least some cases of TN.
Article highlights
. 11% of patients with trigeminal neuralgia reported familial occurrences, thus suggesting that TN occurs as a
familial disorder in an unexpectedly large number of cases.
. WES, filtered to focus on the neuronal electrogenisome, revealed multiple variants in ion channels.
. The results raise the question of whether optimal treatment for patients with familial TN might be different
than for patients without a family history. More work is needed in this area.
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